Peptide bioregulators
Pancragen
Organ-targeted peptide bioregulator designed to support pancreatic function and glucose metabolism.
Approved in Russia Peptide bioregulators Fat loss
- Full name
- Pancragen (Lys-Glu-Asp-Trp, pancreatic bioregulator)
- Also known as
- KEDT
- Regulatory status
- Approved in Russia
Origin
Synthesized from bovine pancreatic tissue extract by Khavinson's group. Registered in Russia as injectable and oral formulations, and in Russian clinical practice for pancreatic and metabolic health since the 1990s.
Mechanism
Proposed to regulate pancreatic islet and acinar cell differentiation, possibly via developmental transcription factors (Pdx1, Pax6, Pax4, Foxa2), normalizing insulin secretion and glucose tolerance.
Research summary
Evidence
A 2013 study showed pancragen stimulated differentiation markers in pancreatic cell cultures, more so in aged cultures. Two primate studies (2014-2015) showed normalized glucose tolerance and insulin dynamics in aged rhesus monkeys, but with small samples (4-9 animals). No randomized human trials exist; evidence is limited to animal and cellular models.
Evidence tier: Approved in Russia — see the methodology note for how this is assessed.
Citations
- Effects of pancragen on the differentiation of pancreatic cells during their ageing — Khavinson et al. 2013
- [Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys] — Goncharova et al. 2015
Reported benefits
- support for pancreatic cell regeneration (preclinical)
- potential normalization of glucose metabolism (primate data)
- claimed anti-diabetic effects
Dosing protocols reported in the literature & community
These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.
| Route | Reported protocol |
|---|---|
| Subcutaneous/intramuscular injection or oral tablet | Primate studies used 50-500 µg/animal/day for 10 days IM; community dosing 10-20 mg subcutaneously, unvalidated in humans. |
Side effects
- minimal reported; glucose/metabolic monitoring data limited
Safety notes
Community & reddit notes (anecdotal — not clinical evidence)
Popular in metabolic-health biohacker circles for glucose control claims. Human evidence is entirely absent, and imported peptide quality is unassured.